News

Voranigo® Celebrates Multi-Regional Prix Galien Triumphs

Voranigo® Celebrates Multi-Regional Prix Galien Triumphs

Voranigo® Recognized with Multiple Prix Galien Awards

Servier's Voranigo® (vorasidenib) has recently achieved remarkable recognition by winning the prestigious Prix Galien Awards in various regions. This acknowledgment serves as a testament to the significant strides made by Voranigo® in benefiting patients diagnosed with glioma. The awards include the Prix Galien USA, the Prix Galien Poland, and the Prix Galien Bridges Awards, all primarily focusing on Best Product for Orphan/Rare Diseases.

Acknowledgment for Innovative Advancements

The Prix Galien Awards highlight innovative advancements within the healthcare sector, specifically recognizing breakthrough products and exceptional research teams in pharmaceutical, biotech, medtech, and digital health arenas. With several awards under its belt, Voranigo® is paving the way for enhanced treatment options for glioma patients worldwide.

2025 Prix Galien Bridges Award

During a recent awards ceremony held in Stockholm, Voranigo® was honored with the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases. This award showcases the commitment that Servier has towards fostering life science innovation across multiple regions, including the Nordic countries and key biopharmaceutical communities from Europe and the Middle East.

Recognition in the USA and Poland

In addition to the Bridges Award, Voranigo® has also been bestowed with the highly esteemed Prix Galien USA Award and the Prix Galien Poland Award in the Best Product category for Orphan/Rare Diseases. These recognitions not only celebrate Servier's dedication to innovation but also validate the potential impact Voranigo® is set to have on patient care.

Commitment to Patients and Innovation

Arnaud Lallouette, Executive Vice-President of Global Medical & Patient Affairs at Servier, expressed gratitude for these accolades, emphasizing their significance in recognizing the scientific advancements Voranigo® brings to glioma patients. Lallouette stated, "We are truly honored to receive these prestigious distinctions in several countries. It recognizes the scientific progress that Voranigo® can bring to patients living with glioma across the world. It rewards Servier's commitment to innovation and to patients as we continue to advance precision oncology for all who stand to benefit."

Clinical Significance of Voranigo®

Voranigo® has received marketing authorization to treat predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma cases associated with specific mutations in adults and adolescents aged 12 years and older. Particularly, it targets individuals diagnosed with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation, provided they weigh at least 40 kg and are not requiring immediate radiotherapy or chemotherapy after surgical interventions.

About Servier

Servier is recognized as an independent international pharmaceutical company dedicated to delivering innovative treatment solutions. As they continue to make strides in oncology and various other therapeutic areas, they remain committed to fostering a healthier future for patients globally. As part of their outreach, Servier encourages following their developments and updates through their official social media platforms.

Frequently Asked Questions

What is Voranigo® and what condition does it treat?

Voranigo® (vorasidenib) is an innovative treatment primarily used for adults and adolescents with specific genetic mutations associated with low-grade gliomas.

Which awards has Voranigo® recently received?

Voranigo® has won the Prix Galien USA, Prix Galien Poland, and the Prix Galien Bridges Awards for its exceptional performance in treating orphan/rare diseases.

What does the Prix Galien Award signify?

The Prix Galien Award is a prestigious accolade that honors significant innovations in the life sciences field, recognizing breakthrough products and outstanding research teams.

Who is Servier?

Servier is an independent international pharmaceutical group committed to providing innovative healthcare solutions and improving patient outcomes through advanced medical research.

What is the significance of the Prix Galien Bridges Award?

The Prix Galien Bridges Award highlights the innovation in life sciences, especially recognizing contributions within the Nordic countries and their connection to key biopharmaceutical sectors in Europe and the Middle East.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Rice Sets Course in Houston’s Thriving Innovation Hub

Updated Category News Views 50

Houston's Innovation Scene Expands The ground's barely settled and already Rice University is shaking up the scene in Houston’s Ion District with the Arc. At nearly 200,000 square feet, this powerhouse is set to bridge the gap between research, industry, and entrepreneurs, pushing ideas from discovery to reality. A Groundbreaking Investment For anyone with half an idea...

Continue Reading
MetaVia's DA-1726 Impresses with Liver Fat Reduction

Updated Category News Views 88

A Statistical Leap in Liver Fat Reduction MetaVia's latest Phase 1 data for DA-1726 makes a splash with a 68% reduction in liver fat, and I can't say I'm not intrigued. When results like these hit the table, it gives those of us who keep a close watch on the biotechnology world reason to pause. The reduction in liver fat isn't just another number; it's a chart-buster...

Continue Reading
PSG's Anna AI Wins Vizient's Innovative Tech Nod

Updated Category News Views 140

Hospital Hiring Gets a Tech Boost In the bustling world of healthcare recruitment, it's like trudging through quicksand with a time bomb strapped to your back. That's where PSG Global Solutions sauntered into the Las Vegas spotlight with Anna AI, their generative AI marvel that just snagged the Innovative Technology designation from Vizient. This ain’t your...

Continue Reading
Skyhawk's Huntington's Trial: A Step Toward Hope in U.S.

Updated Category News Views 84

Breaking Ground in the Fight Against Huntington's The latest shuffle in the relentless pursuit of medical breakthroughs sees Skyhawk Therapeutics rolling their dice in the fight against Huntington's disease (HD) with the U.S. launch of their pivotal FALCON-HD study. HD is a treacherous, progressive disorder that’s been stealing time from patients for far too long. It's...

Continue Reading
Empower Brokerage Draws Talent to North Texas Job Fair

Updated Category News Views 147

Shakeup at the North Texas Job Fair Slinging insurance ain't everyone's dream gig, but some folks find their calling where money meets meaning. The North Texas Job Fair, already known for its heavy foot traffic, saw a unique player strutting their stuff this year—Empower Brokerage. This family-owned insurance agency wasn't just slinging corporate pitch; they offered a...

Continue Reading
AI Factory Revolution: PortCon 2026 Ignites Innovation

Updated Category News Views 53

Shaking Up the Software Game November 2026 is set to be a standout period for tech aficionados, as Port, the AI Software Factory platform, rolls out the red carpet for PortCon, the inaugural AI Software Factory Summit, in San Francisco. This summit is no small fry in the industry kettle—it's going to be a rendezvous where tech heavyweights, including the likes of Uber,...

Continue Reading
Pharmaceutical Navigator ASTHO's Podcast Earns Bronze Anthem Award

Updated Category News Views 99

An Award to Nod At: ASTHO's Public Health Triumph The world of public health isn't generally where you'd find shiny accolades flying around, but when they do, it's worth taking notice. Recently, ASTHO’s podcast, the Public Health Review Morning Edition, snagged a Bronze Anthem Award. Sure, it isn't the gold trophy, but in this high-stakes arena, any medal's a feat! More...

Continue Reading
Reviving Carbide Tools: Resharpening for Cost Control

Updated Category News Views 99

Trading Rust: Resharpening Carbide Cutting Tools Alright, picture this: you've got a toolbox full of worn carbide tools, each looking like they've seen better days. You might toss 'em out and grab some new ones, right? But hold on! Carl Ciesla, a cutting tool vet from Sanborn, NY, is talking all about how resharpening could be your ticket to saving a heap of cash and...

Continue Reading
Koozee Boosts Apparel Design with AI Workflows

Updated Category News Views 108

Revolutionizing Apparel Design with AI If you've ever wondered how tech can make an impact on the fashion world, Koozee's latest update provides an eye-opening look. This isn't about following trends—it's about setting them, and Koozee’s making a bold move with its newest platform enhancements. Introducing Freeform Canvas Koozee has launched the Freeform Canvas, a...

Continue Reading
Major Donations Boost Mesothelioma Research Funding

Updated Category News Views 104

Significant Boosts in Mesothelioma Support November's chill didn't slow down major support for mesothelioma initiatives. On October 22, 2026, during the grand setting of the Foundation's 2026 International Symposium on Malignant Mesothelioma in The Woodlands, Texas, MesoCare.org and Danziger & De Llano, LLP stepped up big time. Their philanthropic moves weren't just about...

Continue Reading

Top 5 Most Recently Viewed Articles

BluSky AI Inc. Transitions to OTCID to Boost Market Visibility

Updated Category News Views 110

BluSky AI Inc. Announces Transition to OTCID Designation BluSky AI Inc. (OTC: BSAI), a trailblazer in the realm of modular AI data center infrastructure, is excited to share a pivotal development: the company will move to the OTCID platform effective July 1, 2025. This change signifies BluSky AI's adherence to higher reporting and compliance standards, which is essential...

Continue Reading
AST SpaceMobile's Stock Price Decline Driven by Note Offering

Updated Category News Views 160

AST SpaceMobile Stock Price Decline AST SpaceMobile Inc. (NASDAQ: ASTS) has recently encountered a notable decline in its share prices. This shift has sparked interest among investors and analysts, raising questions about the factors contributing to this situation. Pricing of Convertible Senior Notes The primary catalyst for this downturn was the company’s announcement...

Continue Reading
Investor Concerns Grow as C3.ai Reports Unexpected Results

Updated Category News Views 82

C3.ai Faces Scrutiny Over Recent Financial Performance C3.ai, Inc. is currently under the microscope as investors express growing concerns following its latest financial announcement. The circumstances surrounding these results have led to inquiries regarding possible securities fraud and improper business practices within the company. Investigation by Pomerantz Law Firm...

Continue Reading
Voranigo® Celebrates Multi-Regional Prix Galien Triumphs

Updated Category News Views 178

Voranigo® Recognized with Multiple Prix Galien Awards Servier's Voranigo® (vorasidenib) has recently achieved remarkable recognition by winning the prestigious Prix Galien Awards in various regions. This acknowledgment serves as a testament to the significant strides made by Voranigo® in benefiting patients diagnosed with glioma. The awards include the Prix Galien USA,...

Continue Reading
Telesat's Financial Performance Highlights for 2024

Updated Category News Views 284

Telesat's Financial Overview Today, Telesat, recognized as one of the largest satellite operators in the world, disclosed its financial results, shedding light on its performance for the recent fiscal year ended December 31, 2024. The company operates under the ticker symbols NASDAQ and TSX: TSAT, which denote its presence on two significant stock exchanges. Financial...

Continue Reading